TY - JOUR AU - Yoo, C. B. AU - Jones, P. A. PY - 2006 DA - 2006// TI - Epigenetic therapy of cancer: past, present and future JO - Nat Rev Drug Discov VL - 5 ID - Yoo2006 ER - TY - JOUR AU - Hashimshony, T. AU - Zhang, J. AU - Keshet, I. AU - Bustin, M. AU - Cedar, H. PY - 2003 DA - 2003// TI - The role of DNA methylation in setting up chromatin structure during development JO - Nature Genet VL - 34 ID - Hashimshony2003 ER - TY - CHAP AU - Cang, S. AU - Liu, D. L. PY - 2009 DA - 2009// TI - Clinical advances in hypomethylating agents for epigenetic therapy of cancer BT - Current Cancer Drug Targets submitted and under review ID - Cang2009 ER - TY - JOUR AU - Marks, P. A. PY - 2007 DA - 2007// TI - Discovery and development of SAHA as an anticancer agent JO - Oncogene VL - 26 ID - Marks2007 ER - TY - JOUR AU - Marks, P. A. AU - Dokmanovic, M. PY - 2005 DA - 2005// TI - Histone deacetylase inhibitors: discovery and development as anticancer agents JO - Expert Opin Investig Drugs VL - 14 ID - Marks2005 ER - TY - JOUR AU - Xu, W. S. AU - Parmigiani, R. B. AU - Marks, P. A. PY - 2007 DA - 2007// TI - Histone deacetylase inhibitors: molecular mechanisms of action JO - Oncogene VL - 26 ID - Xu2007 ER - TY - JOUR AU - Silverman, L. R. AU - Demakos, E. P. AU - Peterson, B. L. AU - Kornblith, A. B. AU - Holland, J. C. AU - Odchimar-Reissig, R. PY - 2002 DA - 2002// TI - Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B JO - J Clin Oncol VL - 20 ID - Silverman2002 ER - TY - JOUR AU - Jabbour, E. AU - Issa, J. P. AU - Garcia-Manero, G. AU - Kantarjian, H. PY - 2008 DA - 2008// TI - Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies JO - Cancer VL - 112 ID - Jabbour2008 ER - TY - JOUR AU - Kantarjian, H. AU - Issa, J. P. AU - Rosenfeld, C. S. AU - Bennett, J. M. AU - Albitar, M. AU - DiPersio, J. PY - 2006 DA - 2006// TI - Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study JO - Cancer VL - 106 ID - Kantarjian2006 ER - TY - JOUR AU - Kantarjian, H. AU - Oki, Y. AU - Garcia-Manero, G. AU - Huang, X. AU - O'brien, S. AU - Cortes, J. PY - 2007 DA - 2007// TI - Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia JO - Blood VL - 109 ID - Kantarjian2007 ER - TY - JOUR AU - Dokmanovic, M. AU - Marks, P. A. PY - 2005 DA - 2005// TI - Prospects: histone deacetylase inhibitors JO - J Cell Biochem VL - 96 ID - Dokmanovic2005 ER - TY - JOUR AU - Dokmanovic, M. AU - Perez, G. AU - Xu, W. AU - Ngo, L. AU - Clarke, C. AU - Parmigiani, R. B. PY - 2007 DA - 2007// TI - Histone deacetylase inhibitors selectively suppress expression of HDAC7 JO - Mol Cancer Ther VL - 6 ID - Dokmanovic2007 ER - TY - JOUR AU - Dokmanovic, M. AU - Clarke, C. AU - Marks, P. A. PY - 2007 DA - 2007// TI - Histone deacetylase inhibitors: overview and perspectives JO - Mol Cancer Res VL - 5 ID - Dokmanovic2007 ER - TY - JOUR AU - Raj, K. AU - John, A. AU - Ho, A. AU - Chronis, C. AU - Khan, S. AU - Samuel, J. PY - 2007 DA - 2007// TI - CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine JO - Leukemia VL - 21 ID - Raj2007 ER - TY - JOUR AU - Kelly, W. K. AU - Richon, V. M. AU - O'Connor, O. AU - Curley, T. AU - Gregor-Curtelli, B. AU - Tong, W. PY - 2003 DA - 2003// TI - Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously JO - Clin Cancer Res VL - 9 ID - Kelly2003 ER - TY - JOUR AU - Kelly, W. K. AU - Marks, P. A. PY - 2005 DA - 2005// TI - Drug insight: Histone deacetylase inhibitors – development of the new targeted anticancer agent suberoylanilide hydroxamic acid JO - Nat Clin Pract Oncol VL - 2 ID - Kelly2005 ER - TY - JOUR AU - Kelly, W. K. AU - O'Connor, O. A. AU - Krug, L. M. AU - Chiao, J. H. AU - Heaney, M. AU - Curley, T. PY - 2005 DA - 2005// TI - Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer JO - J Clin Oncol VL - 23 ID - Kelly2005 ER - TY - JOUR AU - Duvic, M. AU - Talpur, R. AU - Ni, X. AU - Zhang, C. AU - Hazarika, P. AU - Kelly, C. PY - 2007 DA - 2007// TI - Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) JO - Blood VL - 109 ID - Duvic2007 ER - TY - JOUR AU - Olsen, E. A. AU - Kim, Y. H. AU - Kuzel, T. M. AU - Pacheco, T. R. AU - Foss, F. M. AU - Parker, S. PY - 2007 DA - 2007// TI - Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma JO - J Clin Oncol VL - 25 ID - Olsen2007 ER - TY - CHAP AU - Olsen, E. A. AU - Duvic, M. AU - Breneman, D. AU - Pacheco, T. R. AU - Parker, S. AU - Vonderheid, E. C. PY - 2008 DA - 2008// TI - Vorinostat provides prolonged safety and clinical benefit to patients with advanced cutaneous t-cell lymphoma (CTCL) BT - J Clin Oncol ID - Olsen2008 ER - TY - CHAP AU - Siegel, D. S. AU - Hussein, M. A. AU - Belani, C. P. AU - Robert, F. AU - Rizvi, S. AU - Wigginton, J. PY - 2008 DA - 2008// TI - Safety and tolerability of vorinostat – Experience from the vorinostat clinical trial program BT - J Clin Oncol ID - Siegel2008 ER - TY - JOUR AU - Vansteenkiste, J. AU - Van, C. E. AU - Dumez, H. AU - Chen, C. AU - Ricker, J. L. AU - Randolph, S. S. PY - 2008 DA - 2008// TI - Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer JO - Invest New Drugs VL - 26 ID - Vansteenkiste2008 ER - TY - JOUR AU - Crump, M. AU - Coiffier, B. AU - Jacobsen, E. D. AU - Sun, L. AU - Ricker, J. L. AU - Xie, H. PY - 2008 DA - 2008// TI - Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma JO - Ann Oncol VL - 19 ID - Crump2008 ER - TY - JOUR AU - Garcia-Manero, G. AU - Yang, H. AU - Bueso-Ramos, C. AU - Ferrajoli, A. AU - Cortes, J. AU - Wierda, W. G. PY - 2008 DA - 2008// TI - Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes JO - Blood VL - 111 ID - Garcia-Manero2008 ER - TY - CHAP AU - Badros, A. Z. AU - Philip, S. AU - Niesvizk, R. AU - Goloubeva, O. AU - Harris, C. AU - Zweibel, J. PY - 2008 DA - 2008// TI - Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts) BT - J Clin Oncol [Proc Am Soc Clin Oncol] ID - Badros2008 ER - TY - CHAP AU - Chin, K. AU - Hatake, K. AU - Hamaguchi, T. AU - Shirao, K. AU - Doi, T. AU - Noguchi, K. PY - 2008 DA - 2008// TI - A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in Japanese patients with gastrointestinal (GI) cancer BT - J Clin Oncol ID - Chin2008 ER - TY - CHAP AU - Hammers, H. J. AU - Verheul, H. AU - Wilky, B. AU - Salumbides, B. AU - Holleran, J. AU - Egorin, M. J. PY - 2008 DA - 2008// TI - Phase I safety and pharmacokinetic/pharmacodynamic results of the histone deacetylase inhibitor vorinostat in combination with bevacizumab in patients with kidney cancer BT - J Clin Oncol ID - Hammers2008 ER - TY - CHAP AU - Hymes, K. AU - Dummer, R. AU - Sterry, W. AU - Steinhoff, M. AU - Assaf, C. AU - Kerl, H. PY - 2008 DA - 2008// TI - Phase I trial of oral vorinostat in combination with bexarotene in patients with advanced cutaneous T-cell lymphoma BT - J Clin Oncol ID - Hymes2008 ER - TY - JOUR AU - Fan, J. AU - Yin, W. J. AU - Lu, J. S. AU - Wang, L. AU - Wu, J. AU - Wu, F. Y. PY - 2008 DA - 2008// TI - ERalpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor JO - J Cancer Res Clin Oncol VL - 134 ID - Fan2008 ER - TY - JOUR AU - Jang, E. R. AU - Lim, S. J. AU - Lee, E. S. AU - Jeong, G. AU - Kim, T. Y. AU - Bang, Y. J. PY - 2004 DA - 2004// TI - The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen JO - Oncogene VL - 23 ID - Jang2004 ER - TY - JOUR AU - Keen, J. C. AU - Yan, L. AU - Mack, K. M. AU - Pettit, C. AU - Smith, D. AU - Sharma, D. PY - 2003 DA - 2003// TI - A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine JO - Breast Cancer Res Treat VL - 81 ID - Keen2003 ER - TY - JOUR AU - Munster, P. N. AU - Lacevic, M. AU - Schmitt, M. AU - Bicaku, E. AU - Marchion, D. AU - Stephens, A. PY - 2008 DA - 2008// TI - Phase II trial of vorinostat, a histone deacetylase inhibitor to restore the hormone sensitivity to the anti-estrogen tamoxifen in patients with advanced breast cancer having failed prior aromatase inhibitor therapy JO - J Clin Oncol. VL - 26 ID - Munster2008 ER - TY - JOUR AU - Townsley, C. AU - Oza, A. M. AU - Tang, P. AU - Siu, L. L. AU - Pond, G. R. AU - Sarveswaran, P. PY - 2008 DA - 2008// TI - Expanded phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors JO - J Clin Oncol J Clin Oncol. 2008 Mar 10;26(8):1324-30 VL - 26 ID - Townsley2008 ER - TY - JOUR AU - Ramalingam, S. S. AU - Parise, R. A. AU - Ramanathan, R. K. AU - Lagattuta, T. F. AU - Musguire, L. A. AU - Stoller, R. G. PY - 2007 DA - 2007// TI - Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies JO - Clin Cancer Res VL - 13 ID - Ramalingam2007 ER - TY - JOUR AU - Krug, L. M. AU - Curley, T. AU - Schwartz, L. AU - Richardson, S. AU - Marks, P. AU - Chiao, J. PY - 2006 DA - 2006// TI - Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid JO - Clin Lung Cancer VL - 7 ID - Krug2006 ER - TY - CHAP AU - Cheung, E. M. AU - Quinn, D. I. AU - Tsao-Wei, D. D. AU - Groshen, S. G. AU - Aparicio, A. M. AU - Twardowski, P. PY - 2008 DA - 2008// TI - Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy – California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial BT - J Clin Oncol ID - Cheung2008 ER - TY - JOUR AU - Modesitt, S. C. AU - Sill, M. AU - Hoffman, J. S. AU - Bender, D. P. PY - 2008 DA - 2008// TI - A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study JO - Gynecol Oncol VL - 109 ID - Modesitt2008 ER - TY - CHAP AU - Misset, J. AU - Tredaniel, J. AU - Descourt, R. AU - Morot-Sibilot, D. AU - Zalcman, G. AU - Gachard, E. PY - 2008 DA - 2008// TI - Vorinostat in combination with gemcitabine plus platinum in patients with advanced non-small-cell lung cancer: A phase I, dose-escalation study BT - J Clin Oncol ID - Misset2008 ER - TY - CHAP AU - Fouladi, M. AU - Park, J. R. AU - Sun, J. AU - Ingle, A. M. AU - Ames, M. M. AU - Stewart, C. F. PY - 2008 DA - 2008// TI - A phase I trial and pharmacokinetic (PK) study of vorinostat (SAHA) in combination with 13 cis-retinoic acid (13cRA) in children with refractory neuroblastomas, medulloblastomas, primitive neuroectodermal tumors (PNETs), and atypical teratoid rhabdoid tumor BT - J Clin Oncol ID - Fouladi2008 ER - TY - JOUR AU - Richardson, P. AU - Mitsiades, C. AU - Colson, K. AU - Reilly, E. AU - McBride, L. AU - Chiao, J. PY - 2008 DA - 2008// TI - Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma JO - Leuk Lymphoma VL - 49 ID - Richardson2008 ER - TY - JOUR AU - Blumenschein, G. R. AU - Kies, M. S. AU - Papadimitrakopoulou, V. A. AU - Lu, C. AU - Kumar, A. J. AU - Ricker, J. L. PY - 2008 DA - 2008// TI - Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer JO - Invest New Drugs VL - 26 ID - Blumenschein2008 ER - TY - JOUR AU - Finnin, M. S. AU - Donigian, J. R. AU - Cohen, A. AU - Richon, V. M. AU - Rifkind, R. A. AU - Marks, P. A. PY - 1999 DA - 1999// TI - Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors JO - Nature VL - 401 ID - Finnin1999 ER - TY - JOUR AU - Acharya, M. R. AU - Sparreboom, A. AU - Venitz, J. AU - Figg, W. D. PY - 2005 DA - 2005// TI - Rational development of histone deacetylase inhibitors as anticancer agents: a review JO - Mol Pharmacol VL - 68 ID - Acharya2005 ER - TY - JOUR AU - Bolden, J. E. AU - Peart, M. J. AU - Johnstone, R. W. PY - 2006 DA - 2006// TI - Anticancer activities of histone deacetylase inhibitors JO - Nat Rev Drug Discov VL - 5 ID - Bolden2006 ER - TY - JOUR AU - Kraker, A. J. AU - Mizzen, C. A. AU - Hartl, B. G. AU - Miin, J. AU - Allis, C. D. AU - Merriman, R. L. PY - 2003 DA - 2003// TI - Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma JO - Mol Cancer Ther VL - 2 ID - Kraker2003 ER - TY - JOUR AU - Prakash, S. AU - Foster, B. J. AU - Meyer, M. AU - Wozniak, A. AU - Heilbrun, L. K. AU - Flaherty, L. PY - 2001 DA - 2001// TI - Chronic oral administration of CI-994: a phase 1 study JO - Invest New Drugs VL - 19 ID - Prakash2001 ER - TY - JOUR AU - Nemunaitis, J. J. AU - Orr, D. AU - Eager, R. AU - Cunningham, C. C. AU - Williams, A. AU - Mennel, R. PY - 2003 DA - 2003// TI - Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer JO - Cancer J VL - 9 ID - Nemunaitis2003 ER - TY - JOUR AU - Pauer, L. R. AU - Olivares, J. AU - Cunningham, C. AU - Williams, A. AU - Grove, W. AU - Kraker, A. PY - 2004 DA - 2004// TI - Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors JO - Cancer Invest VL - 22 ID - Pauer2004 ER - TY - CHAP AU - Undevia, S. D. AU - Janisch, L. AU - Schilsky, R. L. AU - Loury, D. AU - Balasubramanian, S. AU - Mani, C. PY - 2008 DA - 2008// TI - Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781 BT - J Clin Oncol ID - Undevia2008 ER - TY - JOUR AU - Undevia, S. D. AU - Kindler, H. L. AU - Janisch, L. AU - Olson, S. C. AU - Schilsky, R. L. AU - Vogelzang, N. J. PY - 2004 DA - 2004// TI - A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine JO - Ann Oncol VL - 15 ID - Undevia2004 ER - TY - JOUR AU - Nakajima, H. AU - Kim, Y. B. AU - Terano, H. AU - Yoshida, M. AU - Horinouchi, S. PY - 1998 DA - 1998// TI - FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor JO - Exp Cell Res VL - 241 ID - Nakajima1998 ER - TY - JOUR AU - Ueda, H. AU - Nakajima, H. AU - Hori, Y. AU - Fujita, T. AU - Nishimura, M. AU - Goto, T. PY - 1994 DA - 1994// TI - FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity JO - J Antibiot (Tokyo) VL - 47 ID - Ueda1994 ER - TY - CHAP AU - Doss, H. H. AU - Jones, S. F. AU - Infante, J. R. AU - Spigel, D. R. AU - Willcutt, N. AU - Lamar, R. PY - 2008 DA - 2008// TI - A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors BT - J Clin Oncol ID - Doss2008 ER - TY - CHAP AU - Piekarz, R. AU - Luchenko, V. AU - Draper, D. AU - Wright, J. J. AU - Figg, W. D. AU - Fojo, A. T. PY - 2008 DA - 2008// TI - Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers BT - J Clin Oncol ID - Piekarz2008 ER - TY - JOUR AU - Klimek, V. M. AU - Fircanis, S. AU - Maslak, P. AU - Guernah, I. AU - Baum, M. AU - Wu, N. PY - 2008 DA - 2008// TI - Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes JO - Clin Cancer Res VL - 14 ID - Klimek2008 ER - TY - JOUR AU - Schrump, D. S. AU - Fischette, M. R. AU - Nguyen, D. M. AU - Zhao, M. AU - Li, X. AU - Kunst, T. F. PY - 2008 DA - 2008// TI - Clinical and molecular responses in lung cancer patients receiving Romidepsin JO - Clin Cancer Res VL - 14 ID - Schrump2008 ER - TY - JOUR AU - Stadler, W. M. AU - Margolin, K. AU - Ferber, S. AU - McCulloch, W. AU - Thompson, J. A. PY - 2006 DA - 2006// TI - A phase II study of depsipeptide in refractory metastatic renal cell cancer JO - Clin Genitourin Cancer VL - 5 ID - Stadler2006 ER - TY - JOUR AU - Piekarz, R. L. AU - Frye, A. R. AU - Wright, J. J. AU - Steinberg, S. M. AU - Liewehr, D. J. AU - Rosing, D. R. PY - 2006 DA - 2006// TI - Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma JO - Clin Cancer Res VL - 12 ID - Piekarz2006 ER - TY - JOUR AU - Leoni, F. AU - Fossati, G. AU - Lewis, E. C. AU - Lee, J. K. AU - Porro, G. AU - Pagani, P. PY - 2005 DA - 2005// TI - The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo JO - Mol Med VL - 11 ID - Leoni2005 ER - TY - CHAP AU - Viviani, S. AU - Bonfante, V. AU - Fasola, C. AU - Valagussa, P. AU - Gianni, A. M. PY - 2008 DA - 2008// TI - Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin's lymphoma patients BT - J Clin Oncol ID - Viviani2008 ER - TY - STD TI - Galli M, Salmoiraghi S, Golay J, Gozzini A, Bosi A, Crippa C: A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma: preliminary results. Blood. 2007, 110 (11): ID - ref61 ER - TY - JOUR AU - Bali, P. AU - Pranpat, M. AU - Bradner, J. AU - Balasis, M. AU - Fiskus, W. AU - Guo, F. PY - 2005 DA - 2005// TI - Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors JO - J Biol Chem VL - 280 ID - Bali2005 ER - TY - JOUR AU - Giles, F. AU - Fischer, T. AU - Cortes, J. AU - Garcia-Manero, G. AU - Beck, J. AU - Ravandi, F. PY - 2006 DA - 2006// TI - A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies JO - Clin Cancer Res VL - 12 ID - Giles2006 ER - TY - JOUR AU - Rathkopf, D. E. AU - Wong, B. Y. AU - Ross, R. W. AU - George, D. J. AU - Picus, J. AU - Tanaka, E. PY - 2008 DA - 2008// TI - A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC) JO - J Clin Oncol J Clin Oncol. 2008 Jun 20;26(18):2959-65 VL - 26 ID - Rathkopf2008 ER - TY - CHAP AU - Duvic, M. AU - Vanaclocha, F. AU - Bernengo, M. G. AU - Okada, C. AU - Breneman, D. AU - Zinzani, P. L. PY - 2008 DA - 2008// TI - Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory Cutaneous T-cell Lymphoma (CTCL) BT - J Clin Oncol ID - Duvic2008 ER - TY - JOUR AU - Zhou, N. AU - Moradei, O. AU - Raeppel, S. AU - Leit, S. AU - Frechette, S. AU - Gaudette, F. PY - 2008 DA - 2008// TI - Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor JO - J Med Chem VL - 51 ID - Zhou2008 ER - TY - JOUR AU - Tourneau, C. L. AU - Siu, L. L. PY - 2008 DA - 2008// TI - Promising antitumor activity with MGCD0103 a novel isotype-selective histone deacetylase inhibitor JO - Expert Opin Investig Drugs VL - 17 ID - Tourneau2008 ER - TY - JOUR AU - Siu, L. L. AU - Pili, R. AU - Duran, I. AU - Messersmith, W. A. AU - Chen, E. X. AU - Sullivan, R. PY - 2008 DA - 2008// TI - Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors JO - J Clin Oncol VL - 26 ID - Siu2008 ER - TY - JOUR AU - Garcia-Manero, G. AU - Assouline, S. AU - Cortes, J. AU - Estrov, Z. AU - Kantarjian, H. AU - Yang, H. PY - 2008 DA - 2008// TI - Phase I study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia JO - Blood VL - 112 ID - Garcia-Manero2008 ER - TY - CHAP AU - Hurwitz, H. AU - Nelson, B. AU - O'Dwyer, P. J. AU - Chiorean, E. G. AU - Gabrail, N. AU - Laille, E. PY - 2008 DA - 2008// TI - Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors BT - J Clin Oncol ID - Hurwitz2008 ER - TY - CHAP AU - Crump, M. AU - Andreadis, C. AU - Assouline, S. AU - Rizzieri, D. AU - Wedgwood, A. AU - McLaughlin, P. PY - 2008 DA - 2008// TI - Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study BT - J Clin Oncol ID - Crump2008 ER - TY - CHAP AU - Bociek, R. G. AU - Kuruvilla, J. AU - Pro, B. AU - Wedgwood, A. AU - Li, Z. AU - Drouin, M. PY - 2008 DA - 2008// TI - Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL) BT - J Clin Oncol ID - Bociek2008 ER - TY - JOUR AU - Saito, A. AU - Yamashita, T. AU - Mariko, Y. AU - Nosaka, Y. AU - Tsuchiya, K. AU - Ando, T. PY - 1999 DA - 1999// TI - A synthetic inhibitor of histone deacetylase, MS-27–275, with marked in vivo antitumor activity against human tumors JO - Proc Natl Acad Sci USA VL - 96 ID - Saito1999 ER - TY - JOUR AU - Hess-Stumpp, H. AU - Bracker, T. U. AU - Henderson, D. AU - Politz, O. PY - 2007 DA - 2007// TI - MS-275, a potent orally available inhibitor of histone deacetylases – the development of an anticancer agent JO - Int J Biochem Cell Biol VL - 39 ID - Hess-Stumpp2007 ER - TY - JOUR AU - Gojo, I. AU - Jiemjit, A. AU - Trepel, J. B. AU - Sparreboom, A. AU - Figg, W. D. AU - Rollins, S. PY - 2007 DA - 2007// TI - Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias JO - Blood VL - 109 ID - Gojo2007 ER - TY - JOUR AU - Gore, L. AU - Rothenberg, M. L. AU - O'Bryant, C. L. AU - Schultz, M. K. AU - Sandler, A. B. AU - Coffin, D. PY - 2008 DA - 2008// TI - A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas JO - Clin Cancer Res VL - 14 ID - Gore2008 ER - TY - JOUR AU - Hauschild, A. AU - Trefzer, U. AU - Garbe, C. AU - Kaehler, K. C. AU - Ugurel, S. AU - Kiecker, F. PY - 2008 DA - 2008// TI - Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-4-{[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma JO - Melanoma Res VL - 18 ID - Hauschild2008 ER - TY - JOUR AU - Buggy, J. J. AU - Cao, Z. A. AU - Bass, K. E. AU - Verner, E. AU - Balasubramanian, S. AU - Liu, L. PY - 2006 DA - 2006// TI - CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo JO - Mol Cancer Ther VL - 5 ID - Buggy2006 ER - TY - JOUR AU - Pili, R. AU - Kruszewski, M. P. AU - Hager, B. W. AU - Lantz, J. AU - Carducci, M. A. PY - 2001 DA - 2001// TI - Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis JO - Cancer Res VL - 61 ID - Pili2001 ER - TY - JOUR AU - Camacho, L. H. AU - Olson, J. AU - Tong, W. P. AU - Young, C. W. AU - Spriggs, D. R. AU - Malkin, M. G. PY - 2007 DA - 2007// TI - Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors JO - Invest New Drugs VL - 25 ID - Camacho2007 ER - TY - JOUR AU - Carducci, M. A. AU - Gilbert, J. AU - Bowling, M. K. AU - Noe, D. AU - Eisenberger, M. A. AU - Sinibaldi, V. PY - 2001 DA - 2001// TI - A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule JO - Clin Cancer Res VL - 7 ID - Carducci2001 ER - TY - JOUR AU - Gilbert, J. AU - Baker, S. D. AU - Bowling, M. K. AU - Grochow, L. AU - Figg, W. D. AU - Zabelina, Y. PY - 2001 DA - 2001// TI - A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies JO - Clin Cancer Res VL - 7 ID - Gilbert2001 ER - TY - JOUR AU - Sung, M. W. AU - Waxman, S. PY - 2007 DA - 2007// TI - Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer JO - Anticancer Res VL - 27 ID - Sung2007 ER - TY - JOUR AU - Maslak, P. AU - Chanel, S. AU - Camacho, L. H. AU - Soignet, S. AU - Pandolfi, P. P. AU - Guernah, I. PY - 2006 DA - 2006// TI - Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome JO - Leukemia VL - 20 ID - Maslak2006 ER - TY - JOUR AU - Plumb, J. A. AU - Finn, P. W. AU - Williams, R. J. AU - Bandara, M. J. AU - Romero, M. R. AU - Watkins, C. J. PY - 2003 DA - 2003// TI - Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101 JO - Mol Cancer Ther VL - 2 ID - Plumb2003 ER - TY - JOUR AU - Steele, N. L. AU - Plumb, J. A. AU - Vidal, L. AU - Tjornelund, J. AU - Knoblauch, P. AU - Rasmussen, A. PY - 2008 DA - 2008// TI - A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors JO - Clin Cancer Res VL - 14 ID - Steele2008 ER - TY - JOUR AU - Gimsing, P. AU - Hansen, M. AU - Knudsen, L. M. AU - Knoblauch, P. AU - Christensen, I. J. AU - Ooi, C. E. PY - 2008 DA - 2008// TI - A Phase I clinical trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with advanced haematological neoplasia JO - Eur J Haematol VL - 81 ID - Gimsing2008 ER - TY - CHAP AU - Mackay, H. AU - Hirte, H. W. AU - Covens, A. AU - MacAlpine, K. AU - Wang, L. AU - Tsao, M. S. PY - 2008 DA - 2008// TI - A phase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial BT - J Clin Oncol ID - Mackay2008 ER - TY - JOUR AU - Gottlicher, M. AU - S, M. i. n. u. c. c. i. AU - P, Z. h. u. AU - OH, K. r. a. m. e. r. AU - A, S. c. h. i. m. p. f. AU - S, G. i. a. v. a. r. a. PY - 2001 DA - 2001// TI - Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells JO - EMBO J VL - 20 ID - Gottlicher2001 ER - TY - JOUR AU - Kuendgen, A. AU - Schmid, M. AU - Schlenk, R. AU - Knipp, S. AU - Hildebrandt, B. AU - Steidl, C. PY - 2006 DA - 2006// TI - The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia JO - Cancer VL - 106 ID - Kuendgen2006 ER - TY - JOUR AU - Bug, G. AU - Ritter, M. AU - Wassmann, B. AU - Schoch, C. AU - Heinzel, T. AU - Schwarz, K. PY - 2005 DA - 2005// TI - Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia JO - Cancer VL - 104 ID - Bug2005 ER - TY - JOUR AU - Chavez-Blanco, A. AU - Segura-Pacheco, B. AU - Perez-Cardenas, E. AU - Taja-Chayeb, L. AU - Cetina, L. AU - Candelaria, M. PY - 2005 DA - 2005// TI - Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study JO - Mol Cancer VL - 4 ID - Chavez-Blanco2005 ER - TY - JOUR AU - Atmaca, A. AU - Al-Batran, S. E. AU - Maurer, A. AU - Neumann, A. AU - Heinzel, T. AU - Hentsch, B. PY - 2007 DA - 2007// TI - Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial JO - Br J Cancer VL - 97 ID - Atmaca2007 ER - TY - JOUR AU - Shapiro, T. A. AU - Fahey, J. W. AU - nkova-Kostova, A. T. AU - Holtzclaw, W. D. AU - Stephenson, K. K. AU - Wade, K. L. PY - 2006 DA - 2006// TI - Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study JO - Nutr Cancer VL - 55 ID - Shapiro2006 ER - TY - JOUR AU - Chiao, J. W. AU - Wu, H. AU - Ramaswamy, G. AU - Conaway, C. C. AU - Chung, F. L. AU - Wang, L. PY - 2004 DA - 2004// TI - Ingestion of an isothiocyanate metabolite from cruciferous vegetables inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle arrest JO - Carcinogenesis VL - 25 ID - Chiao2004 ER - TY - JOUR AU - Lu, L. AU - Liu, D. AU - Ma, X. AU - Beklemishev, A. AU - Seiter, K. AU - Ahmed, T. PY - 2006 DA - 2006// TI - The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo JO - Oncol Rep VL - 16 ID - Lu2006 ER - TY - JOUR AU - Lu, Q. AU - Lin, X. AU - Feng, J. AU - Zhao, X. AU - Gallagher, R. AU - Lee, M. Y. PY - 2008 DA - 2008// TI - Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways JO - J Hematol Oncol VL - 1 ID - Lu2008 ER - TY - JOUR AU - Ma, X. AU - Fang, Y. AU - Beklemisheva, A. AU - Dai, W. AU - Feng, J. AU - Ahmed, T. PY - 2006 DA - 2006// TI - Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells JO - Int J Oncol VL - 28 ID - Ma2006 ER - TY - JOUR AU - Wang, L. G. AU - Beklemisheva, A. AU - Liu, X. M. AU - Ferrari, A. C. AU - Feng, J. AU - Chiao, J. W. PY - 2007 DA - 2007// TI - Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer JO - Mol Carcinog VL - 46 ID - Wang2007 ER - TY - JOUR AU - Wang, L. G. AU - Liu, X. M. AU - Fang, Y. AU - Dai, W. AU - Chiao, F. B. AU - Puccio, G. M. PY - 2008 DA - 2008// TI - De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc JO - Int J Oncol VL - 33 ID - Wang2008 ER - TY - JOUR AU - Qian, D. Z. AU - Wang, X. AU - Kachhap, S. K. AU - Kato, Y. AU - Wei, Y. AU - Zhang, L. PY - 2004 DA - 2004// TI - The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 JO - Cancer Res VL - 64 ID - Qian2004 ER - TY - JOUR AU - Remiszewski, S. W. AU - Sambucetti, L. C. AU - Bair, K. W. AU - Bontempo, J. AU - Cesarz, D. AU - Chandramouli, N. PY - 2003 DA - 2003// TI - N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824) JO - J Med Chem VL - 46 ID - Remiszewski2003 ER - TY - JOUR AU - Hurtubise, A. AU - Momparler, R. L. PY - 2006 DA - 2006// TI - Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells JO - Cancer Chemother Pharmacol VL - 58 ID - Hurtubise2006 ER - TY - JOUR AU - Grant, S. PY - 2004 DA - 2004// TI - The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia? JO - Leukemia VL - 18 ID - Grant2004 ER - TY - JOUR AU - Atadja, P. AU - Hsu, M. AU - Kwon, P. AU - Trogani, N. AU - Bhalla, K. AU - Remiszewski, S. PY - 2004 DA - 2004// TI - Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824 JO - Novartis Found Symp VL - 259 ID - Atadja2004 ER - TY - JOUR AU - Atadja, P. AU - Gao, L. AU - Kwon, P. AU - Trogani, N. AU - Walker, H. AU - Hsu, M. PY - 2004 DA - 2004// TI - Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824 JO - Cancer Res VL - 64 ID - Atadja2004 ER -